10 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 10 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Birchview Capital, headquartered in Vermont, is a private equity firm specializing in investments within the technology, services, and healthcare sectors throughout the United States.
Matthew William Strobeck founded Birchview Capital LP in 2014. Currently, he serves as an independent director at Accelerate Diagnostics, Inc., Biodesix, Inc., Monteris Medical Corp., Monteris Medical, Inc., and QuidelOrtho Corp. Previously, he held positions as an independent director at Quidel Corp., director at Santarus, Inc., Yield10 Bioscience, Inc., and Tepha, Inc., and served as a partner at Westfield Capital Management Co. LP. He also worked as a consultant at Thomas Weisel Asset Management LLC. Strobeck holds a doctorate degree from the University of Cincinnati in Ohio and an undergraduate degree from St. Lawrence University.
Birchview Capital serves 12 clients and manages discretionary assets totaling $210,506,714 as per their Form ADV dated August 2023. According to their latest 13F filing for Q4 2023, they managed $127,549,846 in 13F securities, with a top 10 holdings concentration reaching 70.36%. Their largest holding is in Bristol-Myers Squibb Co., with 702,298 shares held.
